Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Abbott has announced late-breaking data from the Amulet LAA Occluder IDE trial, a multicentre, head-to-head study comparing the company's Amplatzer Amulet left atrial appendage (LAA) occluder with the Watchman (Boston Scientific) device to treat patients with atrial fibrillation (AF)
It is part of a class of drugs known as GLP-1 receptor agonists, created for people living with type 2 diabetes but now widely prescribed for individuals seeking weight reduction
Novo Nordisks contractor responsible for collecting adverse event reports was found to be excluding some events based on foreign regulatory rules rather than U.S
Ghrelin is well known for its orexigenic effects
US$ 24.34
US$ 21.31
US$ 21.88
US$ 27.72
US$ 23.35
